Harmonization of molecular monitoring of CML therapy in Europe

被引：170

作者：

Mueller, M. C. ^{[2
]}

Cross, N. C. P. ^{[3
,4
]}

Erben, P. ^{[2
]}

Schenk, T. ^{[2
]}

Hanfstein, B. ^{[2
]}

Ernst, T. ^{[2
,3
,4
]}

Hehlmann, R. ^{[2
]}

Branford, S. ^{[5
]}

Saglio, G. ^{[6
]}

Hochhaus, A. ^{[1
,2
]}

机构：

[1] Univ Klinikum Jena, Dept Hematol Oncol, D-07740 Jena, Germany

[2] Heidelberg Univ, Univ Med Mannheim, Med Klin 3, D-6800 Mannheim, Germany

[3] Salisbury Dist Hosp, Natl Genet Reference Lab, Salisbury, Wilts, England

[4] Univ Southampton, Sch Med, Salisbury, Wilts, England

[5] Inst Med & Vet Sci, Adelaide, SA 5000, Australia

[6] Osped Univ Torino, Div Med Interna & Ematol, Turin, Italy

来源：

LEUKEMIA | 2009年 / 23卷 / 11期

关键词：

BCR-ABL; chronic myeloid leukemia; molecular monitoring; international scale; conversion factor; EUTOS for CML; CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; MINIMAL-RESIDUAL-DISEASE; BCR-ABL TRANSCRIPTS; FUSION GENE TRANSCRIPTS; QUANTITATIVE RT-PCR; SELECTIVE INHIBITOR; CURRENT METHODOLOGY; TYROSINE KINASE; RECOMMENDATIONS;

D O I：

10.1038/leu.2009.168

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The high efficacy of the standard treatment of chronic myeloid leukemia (CML) with imatinib has prompted the need for accurate methods to monitor response at levels below the landmark of complete cytogenetic remission. Quantification of BCR-ABL transcripts has proven to be the most sensitive method available, and has shown prognostic impact with regard to progression-free survival. Until recently, variations in methods used to quantify BCR-ABL made it difficult to compare results between laboratories. An international program is now underway to harmonize the reporting of results according to an international scale (IS). In this review, we consider the background to the IS and the progress that has been made to date, with a particular focus on ongoing harmonization efforts in Europe. We provide recommendations for the propagation of the IS by national or regional laboratory networks. Leukemia (2009) 23, 1957-1963; doi:10.1038/leu.2009.168; published online 27 August 2009

引用

页码：1957 / 1963

页数：7

共 29 条

[1]

[Anonymous], BLOOD

[2]

[Anonymous], BLOOD

[3]

[Anonymous], BLOOD

[4]

[Anonymous], BLOOD

[5] Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet [J].

Baccarani, Michele ;

Saglio, Giuseppe ;

Goldman, John ;

Hochhaus, Andreas ;

Simonsson, Bengt ;

Appelbaum, Frederick ;

Apperley, Jane ;

Cervantes, Francisco ;

Cortes, Jorge ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Frangois ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Niederwieser, Dielger ;

Silver, Richard ;

Hehlmann, Rudiger .

BLOOD, 2006, 108 (06) :1809-1820

[6]

Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1177/096228029900800204

[7] STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT [J].

BLAND, JM ;

ALTMAN, DG .

LANCET, 1986, 1 (8476) :307-310

[8] Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia [J].

Branford, S. ;

Cross, N. C. P. ;

Hochhaus, A. ;

Radich, J. ;

Saglio, G. ;

Kaeda, J. ;

Goldman, J. ;

Hughes, T. .

LEUKEMIA, 2006, 20 (11) :1925-1930

[9] Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials [J].

Branford, Susan ;

Fletcher, Linda ;

Cross, Nicholas C. P. ;

Mueller, Martin C. ;

Hochhaus, Andreas ;

Kim, Dong-Wook ;

Radich, Jerald P. ;

Saglio, Giuseppe ;

Pane, Fabrizio ;

Kamel-Reid, Suzanne ;

Wang, Y. Lynn ;

Press, Richard D. ;

Lynch, Kevin ;

Rudzki, Zbigniew ;

Goldman, John M. ;

Hughes, Timothy .

BLOOD, 2008, 112 (08) :3330-3338

[10] Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate [J].

Cortes, J ;

Talpaz, M ;

O'Brien, S ;

Jones, D ;

Luthra, R ;

Shan, J ;

Giles, F ;

Faderl, S ;

Verstovsek, S ;

Garcia-Manero, G ;

Rios, MB ;

Kantarjian, H .

CLINICAL CANCER RESEARCH, 2005, 11 (09) :3425-3432

← 1 2 3 →